Royalty Pharma plc (RPRX)
NASDAQ: RPRX · Real-Time Price · USD
32.46
-0.29 (-0.89%)
Mar 11, 2025, 4:00 PM EST - Market closed
Royalty Pharma Revenue
In the year 2024, Royalty Pharma had annual revenue of $2.26B, down -3.86%. Royalty Pharma had revenue of $593.64M in the quarter ending December 31, 2024, a decrease of -0.41%.
Revenue (ttm)
$2.26B
Revenue Growth
-3.86%
P/S Ratio
6.43
Revenue / Employee
$22,864,404
Employees
99
Market Cap
18.71B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
RPRX News
- 12 days ago - Royalty Pharma to Present at TD Cowen's 45th Annual Health Care Conference - GlobeNewsWire
- 26 days ago - 17 Upcoming Dividend Increases, Including 3 Kings - Seeking Alpha
- 27 days ago - Royalty Pharma: Delivering Growth With A Positive Story Ahead - Seeking Alpha
- 27 days ago - Royalty Pharma Announces R&D Funding Collaboration With Biogen - GlobeNewsWire
- 4 weeks ago - Royalty Pharma plc (RPRX) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Royalty Pharma Reports Q4 and Full Year 2024 Results - GlobeNewsWire
- 5 weeks ago - Royalty Pharma Announces Sale of MorphoSys Development Funding Bonds - GlobeNewsWire
- 6 weeks ago - Royalty Pharma to Announce Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025 - GlobeNewsWire